A Worldwide Assessment of the Frequency of Suicide, Suicide Attempts, or Psychiatric Hospitalization After Predictive Testing for Huntington Disease

Overview

Journal Am J Hum Genet

Publisher Cell Press

Specialty Genetics

Date 1999 Apr 17

PMID 10205260

Citations 55

Authors

E W Almqvist

M Bloch

R Brinkman

D Craufurd

M R Hayden

Affiliations

Soon will be listed here.

Abstract

Prior to the implementation of predictive-testing programs for Huntington disease (HD), significant concern was raised concerning the likelihood of catastrophic events (CEs), particularly in those persons receiving an increased-risk result. We have investigated the frequency of CEs-that is, suicide, suicide attempt, and psychiatric hospitalization-after an HD predictive-testing result, through questionnaires sent to predictive-testing centers worldwide. A total of 44 persons (0.97%) in a cohort of 4,527 test participants had a CE: 5 successful suicides, 21 suicide attempts, and 18 hospitalizations for psychiatric reasons. All persons committing suicide had signs of HD, whereas 11 (52.4%) of 21 persons attempting suicide and 8 (44.4%) of 18 who had a psychiatric hospitalization were symptomatic. A total of 11 (84.6%) of 13 asymptomatic persons who experienced a CE during the first year after HD predictive testing received an increased-risk result. Factors associated with an increased risk of a CE included (a) a psychiatric history </=5 years prior to testing and (b) unemployed status. The frequency of CEs did not differ between those persons receiving results of predictive testing through linkage analysis in whom there was only changes in direction of risk and those persons receiving definitive results after analysis for the mutation underlying HD. These findings provide insights into the frequency, associated factors, and timing of CEs in a worldwide cohort of persons receiving predictive-testing results and, as such, highlight persons for whom ongoing support may be beneficial.

Citing Articles

Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis.

Van de Roovaart H, Nguyen N, Veenstra T Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004378 PMC: 10674993. DOI: 10.3390/ph16111513.

Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of Fabry disease.

Nakamura K, Mukai S, Takezawa Y, Natori Y, Miyazaki A, Ide Y Mol Genet Metab Rep. 2023; 36:100983.

PMID: 37323223 PMC: 10267638. DOI: 10.1016/j.ymgmr.2023.100983.

Psychosocial Impact of Huntington's Disease and Incentives to Improve Care for Affected Families in the Underserved Region of the Slovak Republic.

Hubcikova K, Rakus T, Muhlback A, Benetin J, Bruncvik L, Petrasova Z J Pers Med. 2022; 12(12).

PMID: 36556162 PMC: 9783383. DOI: 10.3390/jpm12121941.

Ethical Implications of Alzheimer's Disease Prediction in Asymptomatic Individuals through Artificial Intelligence.

Ursin F, Timmermann C, Steger F Diagnostics (Basel). 2021; 11(3).

PMID: 33806501 PMC: 7998766. DOI: 10.3390/diagnostics11030440.

Genetic testing in dementia - utility and clinical strategies.

Koriath C, Kenny J, Ryan N, Rohrer J, Schott J, Houlden H Nat Rev Neurol. 2020; 17(1):23-36.

PMID: 33168964 DOI: 10.1038/s41582-020-00416-1.

References

Oliver J . Huntington's chorea in Northamptonshire. Br J Psychiatry. 1970; 116(532):241-53. DOI: 10.1192/bjp.116.532.241. View

Kenen R, SCHMIDT R . Stigmatization of carrier status: social implications of heterozygote genetic screening programs. Am J Public Health. 1978; 68(11):1116-20. PMC: 1654013. DOI: 10.2105/ajph.68.11.1116. View

Hayden M, Ehrlich R, Parker H, Ferera S . Social perspectives in Huntington's chorea. S Afr Med J. 1980; 58(5):201-3. View

Eldridge R . Inheritance of torsion dystonia in Jews. Ann Neurol. 1981; 10(2):203-5. DOI: 10.1002/ana.410100217. View

Rosenfeld A . At risk for Huntington's disease: who should know what and when?. Hastings Cent Rep. 1984; 14(3):5-8. View

Platt S . Unemployment and suicidal behaviour: a review of the literature. Soc Sci Med. 1984; 19(2):93-115. DOI: 10.1016/0277-9536(84)90276-4. View

Schoenfeld M, Myers R, Cupples L, Berkman B, Sax D, Clark E . Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry. 1984; 47(12):1283-7. PMC: 1028135. DOI: 10.1136/jnnp.47.12.1283. View

Farrer L . Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986; 24(2):305-11. DOI: 10.1002/ajmg.1320240211. View

Kessler S, Field T, Worth L, Mosbarger H . Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet. 1987; 26(2):259-70. DOI: 10.1002/ajmg.1320260204. View

10.

Mastromauro C, Myers R, Berkman B . Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet. 1987; 26(2):271-82. DOI: 10.1002/ajmg.1320260205. View

11.

Kessler S . Psychiatric implications of presymptomatic testing for Huntington's disease. Am J Orthopsychiatry. 1987; 57(2):212-219. DOI: 10.1111/j.1939-0025.1987.tb03531.x. View

12.

Meissen G, Myers R, Mastromauro C, Koroshetz W, Klinger K, Farrer L . Predictive testing for Huntington's disease with use of a linked DNA marker. N Engl J Med. 1988; 318(9):535-42. DOI: 10.1056/NEJM198803033180903. View

13.

Fox S, Bloch M, Fahy M, Hayden M . Predictive testing for Huntington disease: I. Description of a pilot project in British Columbia. Am J Med Genet. 1989; 32(2):211-6. DOI: 10.1002/ajmg.1320320214. View

14.

Brandt J, Quaid K, Folstein S, Garber P, Maestri N, Abbott M . Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease. JAMA. 1989; 261(21):3108-14. View

15.

Mattsson B, Almqvist E . Attitudes towards predictive testing in Huntington's disease--a deep interview study in Sweden. Fam Pract. 1991; 8(1):23-7. DOI: 10.1093/fampra/8.1.23. View

16.

Nance M, LeRoy B, Orr H, Parker T, Rich S, Heston L . Protocol for genetic testing in Huntington disease: three years of experience in Minnesota. Am J Med Genet. 1991; 40(4):518-22. DOI: 10.1002/ajmg.1320400431. View

17.

Bloch M, Adam S, Wiggins S, Huggins M, Hayden M . Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992; 42(4):499-507. DOI: 10.1002/ajmg.1320420416. View

18.

Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O, Trew M . Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992; 42(4):508-15. DOI: 10.1002/ajmg.1320420417. View

19.

Simpson S, Besson J, Alexander D, Allan K, Johnston A . One hundred requests for predictive testing for Huntington's disease. Clin Genet. 1992; 41(6):326-30. DOI: 10.1111/j.1399-0004.1992.tb03407.x. View

20.

Tyler A, Morris M, Lazarou L, Meredith L, Myring J, Harper P . Presymptomatic testing for Huntington's disease in Wales 1987-90. Br J Psychiatry. 1992; 161:481-8. DOI: 10.1192/bjp.161.4.481. View